Major trial takes on Alzheimer's tau tangles with multiple drugs
NCT ID NCT06957418
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study tests whether new drugs that target tau protein in the brain can slow or stop Alzheimer's disease in its early stages. About 900 adults aged 50 to 80 with very mild or no symptoms will receive a tau drug, a combination of a tau drug and donanemab, or donanemab alone. The goal is to see if these treatments reduce tau buildup and preserve memory and thinking over 30 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.